SLC26A3 and hepatocellular carcinoma: Stratified curves demonstrated progressive increases in predicted risk probabilities with higher scores (figure 2C): for PILCRS11, CLD rose from 45% in Q1 to 70% in Q4 and HCC from 10% to 21%; for PILCRS8, CLD from 47% to 53% and HCC from 4% to 9%; and for PILCRSCYP, CLD from 25% to 59% and HCC from 5% to 15% (figure 2C).